ABSTRACT
INTRODUCTION
Alzheimer's disease is a progressive, ultimately fatal, disorder in which certain types of nerve cells in particular areas of the brain degenerate and die for unknown reasons (1) . However, it has been suggested that oxidative damage is one of the most integral neurotoxic mechanisms in both amyloid β (Aβ) accumulation and tau pathologies (2,3,4) . Specifically, increased oxidative damage to brain lipids, carbohydrates, proteins and DNA has been reported to be involved in AD pathogenesis (5,6) . The vulnerable brain regions include the hippocampus and cortical area comprising cell populations involved in catecholaminergic, serotonergic and cholinergic neurotransmission (7-9) . The hippocampus is the processing center for different information, experience and memory consolidation (10) . Various environmental stimuli, such as exploration, stress, or learning, increase acetylcholine (ACh) release to activate hippocampal functions (11) . In addition, the drugs acting on the cholinergic system can improve or worsen cognitive abilities (12) . Consistently, the postmortem brain from Alzheimer's disease patients shows several indices of reduced cholinergic function, including deficits in the enzyme responsible for the synthesis of acetylcholine (ACh), choline acetyl-transferase, reduced ACh release, and loss of cholinergic neurons in the specific brain areas (4) . Scopolamine is muscarinic receptor antagonist with amnestic property that has been used for decades in experimental animals to induce impairment in their performance of a variety of tasks requiring intact working and reference memory (13,14) . For many years, the amnestic action produced in animals by the administration of centrally acting muscarinic cholinergic antagonists, particularly scopolamine, has been a widely used model for the characterization of potential cognition-enhancing drugs (15) . However, the experimental models of memory impairment have been suggested to be of limited value because they fail to replicate the pathological aspects and the progressive degenerative nature of Alzheimer's disease (16) . Despite this limitation, scopolamine-induced memory impairment, particularly when coupled with a version of the inhibitory avoidance task provides a relatively rapid phenotypic screening tool for drug discovery in the field of cognition enhancement.
Methylene blue (MB) is a diaminophenothiazine that has been in clinical use for approximately 100 years to treat a variety of ailments. MB treats congenital and poisoninduced methemoglobinemia; prevents the side effects of chemotherapy (17,18) , and treats septic shock (19) . The dose of MB usually used in clinical settings is between 1 and 2 mg/kg/day (20) ; and signs of toxicity start at higher levels (7.5 mg/kg/day) (21) . The therapeutic potential of MB also has been demonstrated in models for specific ailments. MB protects against endotoxin-induced lung injury, bacterial lipopolysaccharideinduced fever (22, 23) , and cyclosporine injury to the kidney (24) . Methylene blue administration in vivo appears to benefit the central nervous system and cognitive function (25) , protects from methylmalonate induced seizures (26) , and protects from the cognitive decline inflicted by inhibitors of complex IV (27) . The present study aims to study the possible protective effect of MB in scopolamine-induced amnesia in rats and explore the neurochemical basis of this effect.
MATERIALS & METHODS
Experimental animals: male adult Sprague Dawley rats (150-200 g) were kindly provided from our breeding center at NODCAR and kept for a week for acclimatization under normal conditions and constant temperature (25±1C°) with ad libitum water and food until starting the experiment.
Chemicals:
All chemicals, unless specified otherwise, were purchased form Sigma-Aldrich Chemical Co. (St. Louis, MO). Scopolamine and methylene blue were dissolved in saline.
Animal grouping:
A total number of forty eight Sprague Dawley rats with an average weight of 175 ± 5 g, was divided into six groups:  Control group: the rats intraperitoneally administered 1ml saline solution.  Methylene group-2: the rats were intraperitoneally administered single dose of methylene blue (2mg/g).  Methylene group-5: the rats were intraperitoneally administered single dose of methylene blue (5mg/g).  Methylene group-2 plus scopolamine:
the rats were intraperitoneally administered single dose of methylene blue (2 mg/g), followed by scopolamine 30 minutes later (1mg/kg, i.p).  Methylene group-5 plus scopolamine: the rats were intraperitoneally administered single dose of methylene blue (5mg/g), followed by scopolamine 30 minutes later (1mg/kg, i.p).  Scopolamine group: the rats were intraperitoneally administered single dose of scopolamine (1mg/kg).
Passive avoidance test
Passive avoidance test, which is a fear-motivated test classically used to assess the effect of different treatments on memory (28) . The apparatus was equipped with identical illuminated and non-illuminated boxes with a guillotine door (5×5cm). The illuminated compartment (20×20×20cm) contained a 50-W bulb, and the floor of nonilluminated compartment (20×20×20cm) was composed of 2 mm stainless steel rods spaced 1 cm apart. A rat was gently placed in the illuminated compartment for an acquisition trial, and the door between the two compartments was opened after 10 sec. When the rat entered the dark compartment, the door was closed and an electrical foot shock (0.5 mA, 3 sec duration) was delivered through the stainless steel rods. Twenty-four hours after this acquisition trial, the mouse was again placed in the illuminated compartment for a retention trial. The time taken for a mouse to enter the dark compartment after door opening was defined as latency time for both acquisition and retention trials. Latency for entering the dark compartment was recorded up to 300 sec. If a rat did not enter the dark compartment within 300 sec., the rat was removed and assigned a latency score of 300 sec. Methylene blue and scopolamine were dissolved in 0.9% saline. Methylene blue doses were given 1 h after the acquisition trial. Memory impairment was induced in rat with scopolamine (1 mg/kg, i.p.) 30 min after methylene blue treatment. The control group received saline solution only. Following the behavioral study, the rats were decapitated and brain was dissected into cortex and hippocampus. 
DISCUSSION
The present study showed that scopolamine treated rats exhibited decreased level of ACh and increased catalytic activity of total cholinesterase in both brain cortex and hippocampus, due to the increased turn over of ACh as a result of ChE activation under scopolamine treatment. It might be speculated that scopolamine reversibly binds to some allosteric site in ChE molecule causing a change in its secondary structure leading to increased catalytic activity and decreased ACh content. . In addition, methylene Blue (MB),is efficiently trapped in the brain and its concentration is over 10 times higher in the brain than in the circulation one hour after systemic administration (48) , indicating a rapid and extensive accumulation in the nervous system. Moreover, MB has been used as a neuroprotective agent in druginduced encephalopathy, dementia and manic-depressive psychosis (49) . In the present study scopolamine treated group showed defective performance in passive avoidance task, indicating the occurrence of the amnesia. This effect might be, at least, due to cholinergic dysfunction and/or oxidative stress. In accordance, previous studies indicated the (12,53) . The study provides a demonstration of the neuroprotective effects of methylene blue in scopolamine-induced amnesia. Coadministration of MB, within the safe range (2-5 mg/kg, i.p.), provided effective protection against oxidative stress and cholinergic dysfunction, the main culprits in Alzheimer's disease. Although methylene blue merely presents a protective potential and may not cure Alzheimer's disease, yet any drug that reverses symptoms, improves quality of life, delays neurodegeneration, and saves huge costs, represents an important step in progress towards curing Alzheimer's disease. 
